Eagle Pharmaceuticals (NASDAQ: EGRX) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Profitability

This table compares Eagle Pharmaceuticals and TherapeuticsMD’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Eagle Pharmaceuticals 39.32% 66.30% 48.44%
TherapeuticsMD -462.94% -77.41% -68.24%

Analyst Recommendations

This is a breakdown of current ratings and price targets for Eagle Pharmaceuticals and TherapeuticsMD, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eagle Pharmaceuticals 1 0 3 0 2.50
TherapeuticsMD 0 1 8 0 2.89

Eagle Pharmaceuticals currently has a consensus target price of $72.50, indicating a potential upside of 25.52%. TherapeuticsMD has a consensus target price of $14.88, indicating a potential upside of 123.68%. Given TherapeuticsMD’s stronger consensus rating and higher possible upside, analysts clearly believe TherapeuticsMD is more favorable than Eagle Pharmaceuticals.

Valuation & Earnings

This table compares Eagle Pharmaceuticals and TherapeuticsMD’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Eagle Pharmaceuticals $245.88 million 3.56 $83.99 million $5.95 9.71
TherapeuticsMD $18.26 million 74.30 -$88.99 million N/A N/A

Eagle Pharmaceuticals has higher revenue and earnings than TherapeuticsMD.

Summary

Eagle Pharmaceuticals beats TherapeuticsMD on 5 of the 9 factors compared between the two stocks.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka. Its advanced candidates include EP-3101 (bendamustine Resistance Temperature Detectors (RTD)) (EP-3101), EP-4104 (dantrolene sodium for exertional heat stroke (EHS)) (EP-4104), EGL-4104-C-1702 (dantrolene sodium for drug induced hyperthermia), EP-5101 (pemetrexed) (EP-5101) and EGL-5385-C-1701 (fulvestrant). Its product portfolio focuses on oncology, critical care and orphan diseases. Bendamustine is an alkylating agent approved for use in chronic lymphocytic leukemia (CLL), and indolent B-cell non-Hodgkin’s lymphoma (NHL), that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc. is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort. With its SYMBODA technology, it is developing hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through dosage forms and administration routes. Its product line includes vitaTrue, vitaPearl, vitaMedMD Plus, vitaMedMD One Prenatal Multivitamin, vitaMedMD Plus Rx Prenatal Multivitamin, vitaMedMD One Rx Prenatal Multivitamin, vitaMedMD Iron 21/7, vitaMedMD Vitamin D3 50,000 IU, BocaGreenMD Prena1 Pearl and BocaGreenMD Prena1 Chew.

Receive News & Stock Ratings for Eagle Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.